© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
CE: HER2-Positive Metastatic Breast Cancer and What Targeted Therapy Means for Managed Care
This activity is supported by educational grants from Seagen Inc., Daiichi Sankyo, and AstraZeneca.
This activity is supported by educational grants from Seagen Inc., Daiichi Sankyo, and AstraZeneca.
EDUCATIONAL OBJECTIVES
At the completion of this activity, the participant will be able to:
- Analyze evolving guideline recommendations for patient management in the treatment of HER2+ metastatic breast cancer.
- • Identify financial considerations associated with HER2+ metastatic breast cancer and the impact of therapy on patient care.
FACULTY
Laura Bobolts, PharmD, BCOP
Senior Vice President , Clinical Strategy and Growth
Oncology Analytics, Inc, Plantation, Florida
Kelly Gaertner, PharmD, BCOP, BCPS
Oncology Clinical Pharmacy Specialist
Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania
Philip Schwieterman, PharmD, MHA
Director of Oncology and Pediatric Pharmacy
UK HealthCare, Lexington, Kentucky
TARGET AUDIENCE: Oncology pharmacists, managed care pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: February 15, 2021
EXPIRATION DATE: August 15, 2021
ESTIMATED TIME TO COMPLETE ACTIVITY: 1 hour
FEE: This lesson is offered for free at www.pharmacytimes.org.
Related Content: